New documents have investigators questioning inconsistencies and omissions in data reporting in the PLATO trial, building on ...

A HER2-positive status reflects breast cancer cells with extra copies of the HER2 gene, or higher expression of HER2 proteins ...

The benefit of the PARP inhibitor in patients with germline BRCA pathogenic variants remains evident 10 years after the first ...

An investigation published in The BMJ raises new concerns over the landmark clinical trial (PLATO) that was used to gain ...

A new report questions the efficacy of a drug approved by the FDA to help precent heart attack and stroke in people with a ...

Shares of AstraZeneca PLC AZN inched up 0.28% to £105.68 Thursday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 0.12% to 8,311.76.

In a report released today, Steve Scala from TD Cowen maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...

Tracer Biotechnologies, a next-generation diagnostics company, today announced a multi-year project with AstraZeneca (LSE/STO/Nasdaq: AZN). The agreement will enable AstraZeneca to use Tracer's ...

Most positive tests for RSV so far this season in Canada have been among the youngest, federal data suggests. And while ...

NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ...

AstraZeneca PLC ADR closed $20.28 below its 52-week high ($87.68), which the company achieved on August 30th.